Kolexia
Bennouna-Louridi Jaafar Oncologie médicale
Bennouna-Louridi Jaafar
Oncologie médicale
Hôpital Foch
Suresnes, France
550 Activités
1.8 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Tumeurs colorectales Adénocarcinome Métastase tumorale Carcinomes Tumeurs du côlon Carcinome épidermoïde

Collaborateurs

Voir plus
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Taieb Julien
Taieb Julien
Hôpital Européen Georges Pompidou, Paris, France
Ghiringhelli Francois
Ghiringhelli Francois
Centre Georges-François Leclerc, Dijon, France
Francois Eric
Francois Eric
Centre Antoine Lacassagne, Nice, France

Industries

Voir plus
AstraZeneca
28 collaboration(s)
Dernière en 2023
MSD
28 collaboration(s)
Dernière en 2023
BMS
21 collaboration(s)
Dernière en 2023
Janssen
19 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975): A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
Essai Clinique (Merck & Co.)   20 mars 2024
CANOPY-1: A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Essai Clinique (Novartis)   18 mars 2024
innovaTV 207: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Essai Clinique (Seagen)   15 mars 2024
iintune-1: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Essai Clinique (Takeda Pharmaceutical)   07 mars 2024
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Essai Clinique (Lilly)   27 février 2024
MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial
Essai Clinique (AstraZeneca)   26 février 2024
FIPO23: Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid Tumors
Essai Clinique (Xenothera SAS)   19 janvier 2024
CheckMate 9LA: A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Essai Clinique (BMS)   05 janvier 2024
R2D2: Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   18 décembre 2023
Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer.
Clinical lung cancer   13 décembre 2023